AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01516489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 1
Description: Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to.
Study NCT01516489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 2
Description: Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to. The exact dollar amounts for the Voucher-Based Incentive, Lottery-Based Incentive, and Raffle-Based Incentive arms will be based on the results of Stage 1.
Study NCT04203212 — intervention group
Intervention type: DRUG
Intervention: Goserelin Acetate
Description: Goserelin the a GnRH analog that will be administered to achieve menstrual cessation for 6 months
Study NCT01263067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifespan Integration Therapy
Description: LI treatment guides the client to imaginally visit past memories, and then leads her or him forward through time to the present using a concept referred to as the time line. Beginning with the individual's memories from the traumatic experience, the time line first follows memories from the days and weeks after the trauma, then season by season to the present, and is reviewed in ongoing sessions as increasing details of the traumatic event are uncovered.
Study NCT01263067 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifespan Integration- Control
Description: Participants selected for the control group will be treated 4 weeks following initial contact. Treatment is the same as for the Experimental Group.
Study NCT03283046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Dose Escalation Phase Starting Dose: Nivolumab 1 mg/kg by vein over 60 minutes every 3 weeks for 4 doses, followed by Nivolumab 240 mg by vein every 2 weeks until disease progression or unacceptable toxicity on Days 1 and 15 each cycle.~Dose Expansion Phase Starting Dose: Maximum tolerated dose (MTD) from Dose Escalation Phase.~Maintenance: Nivolumab 240 mg by vein every 2 weeks until disease progression or unacceptable toxicity on Days 1 and 15 each cycle.
Study NCT03283046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dose Escalation and Dose Expansion Dose: Lenalidomide 25 mg by mouth on Days 1- 14 in 21 day cycles and Days 1-21 in 28 day cycles.~Maintenance: Lenalidomide 10 mg by mouth on Days 1-21.
Study NCT03283046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dose Escalation and Dose Expansion Dose: Dexamethasone 40 mg by mouth on Days 1,8,15 in 21 day cycles and 1,8,15 and 22 in 28 day cycles
Study NCT03283046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Dose Escalation and Dose Expansion Dose: Ipilimumab 1 mg/kg by vein over 90 minutes every 3 weeks for 4 doses.~Maintenance: If there is evidence of disease progression, Ipilimumab reintroduced at 3 mg/kg every 3 weeks for 4 doses. (Nivolumab dose in Combination determined by the phase 1 portion).
Study NCT02964338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Fremanezumab will be administered as per the dose and schedule specified in the respective arms.
Study NCT02964338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to fremanezumab will be administered as per the schedule specified in the respective arms.
Study NCT02964338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to fremanezumab will be administered as per the schedule specified in the respective arms.
Study NCT02829658 — intervention group
Intervention type: BEHAVIORAL
Intervention: Psychologic test
Description: Assessment by a psychologist including the Structured Interview for Diagnostic and Statistical Manual (DSM)-IV Personality Disorders (SIDP-IV) was given straight to those who had a score above 28. This questionnaire allowed us to distinguish one group of subjects with BPD and a group with other PD (without BPD). Clinical evaluation included Axis I (MINI), Axis II (SIDP-IV), psychopathological features (YSQ-I, Defense Style Questionnaire (DSQ-40), demographic variables and therapeutic alliance (Haq-II).
Study NCT02829658 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02812641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPF-CCRT (run-in)
Description: Six patients will be enrolled in run-in phase. If \<= 1 patient developed dose-limiting toxicity, the trial will be continued to randomized phase. If > 1 patients developed dose-limiting toxicities, the protocol will be discontinued.
Study NCT02812641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPF-CCRT (randomized)
Description: Twenty-two patients will be planned to assign to the experimental arm
Study NCT02812641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-CCRT (randomized)
Description: Twenty-two patients will be planned to assign to the active control arm
Study NCT01292707 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard national training
Study NCT01292707 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HW
Description: Prescribing staff in the intervention facilities will receive the same package of nationally-approved training in RDT use as will be provided to prescribers in control facilities. Following this, prescribers in the intervention facilities will be invited to participate in 3 small group training modules delivered in an interactive style lasting approximately 11/2 hours, with one session repeated between the 6th and 7th month of the trial
Study NCT01292707 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HWC
Description: The health worker-community arm will receive the same intervention as the health workers arm but with the addition of an intervention aimed at patients. This will consist of community sensitisation, clinic posters and providing a leaflet to each RDT-tested patient or caretaker giving details of the test and the corresponding treatment provided.
Study NCT03441685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semantic cues (perform action), syntactic cues (sentence frame), or combined semantic and syntactic cues
Description: Verb Learning Session Teaching phase. The examiner labels each target word and performs the action 6 times in each condition. She elicits the target word from the participant 2 times per word per condition and provides feedback on accuracy.~Testing phase. Receptive probes are administered after every 2 words are taught. Expressive probes are at the end of the condition. For receptive probes, the examiner asks the participant to identify novel verbs and for expressive probes, the examiner asks the child to label the novel action. Testing after 2 items is designed to decrease memory load. Participants have a brief break between conditions.~Data are collected on: a) child responses on standardized assessments, (b) responses to verb learning probes, (c) parent responses to intake form, and (d) relevant medical history from electronic medical record.~None of the above procedures present more than minimal risk to participants or research staff. Vanderbilt IRB approved all procedures.
Study NCT01965002 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRgHIFU
Description: The InSightec ExAblate 2000 magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system is a non-invasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue
Study NCT01965002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 325 mg PO for deep venous thrombosis (DVT) prophylaxis initiated 2 hours prior to magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) treatment
Study NCT01965002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: 40 mg by subcutaneous (SC) administration, for deep venous thrombosis (DVT) prophylaxis initiated 2 hours prior to magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) treatment
Study NCT03397121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
Study NCT03397121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
Study NCT02380937 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ablation for typical atrial flutter
Description: ablation for typical atrial flutter
Study NCT02380937 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vision Ablation Catheter
Study NCT03540069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Group Cervical Cancer Screening Education Curriculum
Description: a multi-modal peer education curriculum directed at a multi-level audience and aimed at motivating women to seek cervical cancer screening services.
Study NCT05637307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel node procedure
Description: Injection of radio-active tracer in the tumor before brachytherapy treatment, visualization of sentinel nodes by SPECT, and extirpation of sentinel nodes by surgery
Study NCT03523195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete exercise program
Study NCT03523195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive written information on healthy exercise and diet recommendations
Study NCT03523195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Blood tests
Study NCT03523195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Blood tests
Study NCT03523195 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring Device
Description: Wear Fitbit
Study NCT03523195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03523195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03523195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Performance Testing
Description: Performance of physical tests
Study NCT03523195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Performance of physical tests
Study NCT03791801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: the reversal of neuromuscular blockade with sugammadex compared to neostigmine.
Study NCT03791801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: the reversal of neuromuscular blockade with sugammadex compared to neostigmine.
Study NCT03791801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Both groups will receive rocuronium for paralysis during intubation
Study NCT00720785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Parenteral formulation. It is supplied as a 3.5 mg single use vial containing a sterile lyophilized powder that requires reconstitution.
Study NCT00720785 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Description: NK Cell Infusion
Study NCT03791801 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: The reversal of neuromuscular blockade with sugammadex compared to neostigmine/glycopyrrolate
Study NCT02103023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod ointment
Description: 5% 250mg imiquimod ointment
Study NCT02103023 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Imiquimod ointment
Description: 5% 250mg imiquimod ointment
Study NCT02103023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aqueous cream
Description: aqueous cream
Study NCT02103023 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intradermal influenza vaccine
Description: intradermal trivalent influenza vaccine (Intanza15)
Study NCT02103023 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intradermal influenza vaccine
Description: intradermal trivalent influenza vaccine (Intanza15)
Study NCT02103023 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular influenza vaccine
Description: intramuscular trivalent influenza vaccine (Vaxigrip)
Study NCT02683239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab
Description: Participants will receive sub-cutaneous (SC) injections of fasinumab
Study NCT02683239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive sub-cutaneous (SC) injections of matching placebo
Study NCT01296854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spa therapy
Description: 3 weeks of spa therapy
Study NCT01853683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conservative Management
Study NCT01853683 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative Management
Study NCT03352492 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superior laser peripheral iridotomy
Description: Iridotomy placement between 11:00 and 1:00 o'clock
Study NCT03352492 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporal laser peripheral iridotomy
Description: Iridotomy placement at 3:00 or 9:00 o'clock
Study NCT04152083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: Injection for IV administration
Study NCT04152083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection for IV administration
Study NCT02064699 — intervention group
Intervention type: BIOLOGICAL
Intervention: CMV Infection
Description: Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for.~Using the QuantiFERON-CMV test for predicting the risk of CMV infection in the transplanted immune against CMV.
Study NCT03711305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1316
Description: SHR-1316 intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6) and maintenance phase.
Study NCT03711305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
Study NCT03711305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
Study NCT03711305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
Study NCT03711305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6).
Study NCT03711305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion will be administered during the induction phase (Cycles 1-4 or 6) and maintenance phase.
Study NCT02858271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-9778 subcutaneous injection
Study NCT05035875 — intervention group
Intervention type: DEVICE
Intervention: ultrasonography
Description: ultrasound assessment of diaphragm function
Study NCT00809536 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: 225 mg q12, oral PD 0332334 immediate release formulation on Days 1 through 5; Single, oral, 500 mg dose of metformin immediate release
Study NCT00809536 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Single, oral, 500 mg of metformin immediate release
Study NCT00809536 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PD 0332334
Description: 500 mg q12, oral metformin immediate release administered on Days 1 through Day 6 Single, oral, 300 mg dose of PD 0332334 immediate release formulation administered on Day 3
Study NCT00809536 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PD 0332334
Description: Single, oral, 300 mg dose of PD 0332334 immediate release formulation
Study NCT03943355 — intervention group
Intervention type: OTHER
Intervention: Patient before cohort (2005-2010)
Description: The NOM protocol with AE was recognized and accepted after our previous study reported in 2004.
Study NCT03943355 — intervention group
Intervention type: OTHER
Intervention: Patient after cohort (2011-2016)
Description: The protocol of NOM became more aggressively and strictly adhered to since 2011.
Study NCT04391179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipyridamole 100 Milligram(mg)
Description: Drug will be given for 14 days while in the hospital.
Study NCT04391179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo will be given for 14 days while in the hospital.
Study NCT04553081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual versus triple therapy in treatment of HIV-1 infection.
Description: cfr arm description
Study NCT00716807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine plus naloxone
Description: Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).
Study NCT00716807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nalbuphine plus placebo
Description: Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
Study NCT00716807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine plus naloxone
Description: Patient group: burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).
Study NCT00716807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nalbuphine plus placebo
Description: Patient group: Burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
Study NCT01831427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Andecaliximab
Description: Andecaliximab administered by intravenous (IV) infusion or subcutaneous (SC) injection
Study NCT04137107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given standard of care oxaliplatin
Study NCT04137107 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: Given standard of care oxaliplatin
Study NCT04137107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine Hydrochloride
Description: Given PO
Study NCT04137107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Given PO
Study NCT04137107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04137107 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03936400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple-based intervention and and evaluation of effectiveness in increasing adjustment of sexuality and intimacy
Description: Three face-to-face therapeutic conversations and an optional web-based evidence based information (about sexual consequences of cancer treatment)
Study NCT01617577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF; filgrastim
Description: The drug is administered s.c. at a dose of 10 microg/kg daily for 5 days
Study NCT01617577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle (D5W or 5% dextrose solution) is administered subcutaneously daily for 5 days
Study NCT00913107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamictal®
Description: The regime of prescription for Lamictal® during the clinical trials was as follows:~1. 50 mg twice daily for 10days, followed by,~2. 100 mg twice daily for the next 10days, followed by,~3. 100 mg thrice daily for the next10 days, followed by,~4. 100 mg four times daily for the final 10 days.
Study NCT00913107 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamictal®
Description: The regime of prescription for Lamictal® during the clinical trials was as follows:~1. 50 mg twice daily for 10days, followed by,~2. 100 mg twice daily for the next 10days, followed by,~3. 100 mg thrice daily for the next10 days, followed by,~4. 100 mg four times daily for the final 10 days.